Ontology highlight
ABSTRACT: Background
Oropharyngeal cancer (OPC) exhibits diverse immunological properties; however, their implications for immunotherapy are unknown.Methods
We analysed 37 surgically resected and nine recurrent or metastatic anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)-treated OPC tumours. OPCs were classified into immune-rich (IR), mesenchymal (MS) and xenobiotic (XB) subtypes based on RNA-sequencing data.Results
All IR type tumours were human papillomavirus (HPV) positive, most XB types were HPV negative, and MS types showed mixed HPV status. The IR type showed an enriched T cell exhaustion signature with PD-1+ CD8+ T cells and type I macrophages infiltrating the tumour nest on multiplex immunohistochemistry. The MS type showed an exclusion of CD8+ T cells from the tumour nest and high MS and tumour growth factor-β signatures. The XB type showed scant CD8+ T cell infiltration and focal CD73 expression. The IR type was associated with a favourable response signature during anti-PD-1/PD-L1 therapy and showed a high APOBEC mutation signature, whereas the MS and XB types showed resistance signature upregulation. Among anti-PD-1/PD-L1-treated OPC patients, the IR type showed a favourable clinical response (3/4 patients), whereas the XB type showed early progression (3/3 patients).Conclusion
Our analysis classified OPCs into three subtypes with distinct immune microenvironments that are potentially related to the response to anti-PD-1/PD-L1 therapy.
SUBMITTER: Kim MH
PROVIDER: S-EPMC7251088 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature
Kim Min Hwan MH Kim Jae-Hwan JH Lee Ji Min JM Choi Jae Woo JW Jung Dongmin D Cho Hojin H Kang Hyundeok H Hong Min Hee MH Heo Su Jin SJ Kim Se Heon SH Choi Eun Chang EC Kim Da Hee DH Park Young Min YM Kim Sangwoo S Yoon Sun Och SO Koh Yoon Woo YW Cho Byoung Chul BC Kim Hye Ryun HR
British journal of cancer 20200401 11
<h4>Background</h4>Oropharyngeal cancer (OPC) exhibits diverse immunological properties; however, their implications for immunotherapy are unknown.<h4>Methods</h4>We analysed 37 surgically resected and nine recurrent or metastatic anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)-treated OPC tumours. OPCs were classified into immune-rich (IR), mesenchymal (MS) and xenobiotic (XB) subtypes based on RNA-sequencing data.<h4>Results</h4>All IR type tumours were human papillomavirus (H ...[more]